作者
Scott D Solomon, John JV McMurray, Brian Claggett, Rudolf A de Boer, David DeMets, Adrian F Hernandez, Silvio E Inzucchi, Mikhail N Kosiborod, Carolyn SP Lam, Felipe Martinez, Sanjiv J Shah, Akshay S Desai, Pardeep S Jhund, Jan Belohlavek, Chern-En Chiang, C Jan Willem Borleffs, Josep Comin-Colet, Dan Dobreanu, Jaroslaw Drozdz, James C Fang, Marco Antonio Alcocer-Gamba, Waleed Al Habeeb, Yaling Han, Jose Walter Cabrera Honorio, Stefan P Janssens, Tzvetana Katova, Masafumi Kitakaze, Béla Merkely, Eileen O’Meara, Jose Francisco Kerr Saraiva, Sergey N Tereshchenko, Jorge Thierer, Muthiah Vaduganathan, Orly Vardeny, Subodh Verma, Vinh Nguyen Pham, Ulrica Wilderäng, Natalia Zaozerska, Erasmus Bachus, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde
发表日期
2022/9/22
期刊
New England Journal of Medicine
卷号
387
期号
12
页码范围
1089-1098
出版商
Massachusetts Medical Society
简介
Background
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain.
Methods
We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis.
Results
Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the …
引用总数
学术搜索中的文章
SD Solomon, JJV McMurray, B Claggett, RA de Boer… - New England Journal of Medicine, 2022